research Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience
Baricitinib effectively reduces hair loss in severe alopecia areata and is generally safe.
Search
for
Sort by
Research
630-660 / 1000+ results
research Proceedings of the RAMI Intern Section Meeting, 18th January 2014
The meeting discussed medical findings, including benefits of certain treatments for cancer and heart conditions, and highlighted issues like poor adherence to preventive measures and skill gaps among interns.
research Serial trichoscopy vs. modified hair pull test for monitoring the disease activity and treatment response of localized alopecia areata
Serial trichoscopy is more reliable than the modified hair pull test for tracking alopecia areata.
research Comparative Evaluation of Superficial Cryotherapy vs Intralesional Triamcinolone in Alopecia Areata at a Tertiary Care Center: A Dermoscopic and Clinical Study in Middle-aged Adults
Intralesional triamcinolone is more effective than cryotherapy for treating alopecia areata in middle-aged adults.
research Industry updates from the field of stem cell research and regenerative medicine in June 2019
In June 2019, the stem cell research field saw major progress, including new clinical trials, FDA approvals, and industry collaborations.
research 104 Flibanserin Subset Analyses and the Androgenics of Hypoactive Sexual Desire Disorder
Flibanserin's effectiveness for low sexual desire in premenopausal women may vary based on hormone levels, with normal hormone levels showing better responses.
research Are finasteride-related penile curvature/Peyronie’s disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases
Finasteride may be linked to Peyronie’s disease, but more research is needed.
research Characteristics and Outcomes of Patients on Tofacitinib for Alopecia Areata or Rheumatoid Arthritis: A Retrospective Cohort Study
Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.
research CLINICAL NUTRITION PROGRAM IMPROVES SENSORY LOSS IN A 60 YEAR OLD TRUCK DRIVER WITH ANTI-MAG NEUROPATHY
A clinical nutrition program improved sensory and motor function in a 60-year-old with anti-MAG neuropathy.
research Alefacept for Severe Alopecia Areata
Alefacept does not effectively treat severe alopecia areata.
research All Subcomponents of the Cutaneous Lupus Erythematosus Disease Area and Severity Index–Activity (CLASI-A) are Relevant to Identify and Detect Changes in Skin Activity
All parts of the CLASI-A score are important for assessing skin activity in cutaneous lupus erythematosus.
research Referee report. For: Recent advances in treatment for Benign Prostatic Hyperplasia [version 1; referees: 2 approved]
BPH treatment improved with personalized medicine, new drugs, and less invasive surgeries.
research Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours
The drug combination was safe and showed promise in treating advanced tumors.
research Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double‐blind placebo‐controlled trial
The new clobetasol propionate foam is effective and safe for treating alopecia areata.
research 860 Understanding cellular & molecular responses in the treatment of pediatric lymphatic anomalies
Sirolimus and propranolol may reduce abnormal cell growth and improve lymphatic malformations in children.
research Broad laboratory testing does not show utility for telogen effluvium: a retrospective analysis of 22-million laboratory results using TriNetX
research Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
research Preclinical Development and Phase I Study of ZSYY001 , a Polymeric Micellar Paclitaxel for Advanced Solid Tumor
ZSYY001 is safe, well-tolerated, and shows promise for treating advanced solid tumors.
research Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.
research The Free Communications of the Eighth Clinical Congress (Virtual) of the Gulf Chapter of the American Association of Clinical Endocrinologists; November 5–7, 2020
I'm sorry, but I can't provide a summary without the content of the document.
research Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib
Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.
research Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique
Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.
research Italian National Registry of Alopecia Areata: an epidemiological study of 699 Italian patients
Alopecia areata is hard to manage and affects quality of life.
research Drug repurposing: Clinical practices and regulatory pathways
Drug repurposing offers faster, cheaper drug development but faces challenges like safety, ethics, and funding.
research Alefacept for Severe Alopecia Areata: A Randomized, Double-blind, Placebo-Controlled Study
research A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia
MK-0773 safely increased muscle mass but did not improve muscle strength or function in elderly women with sarcopenia.
research 320 An open label clinical trial of Abatacept (CTLA4-Ig) for alopecia areata
Abatacept may help some people with alopecia areata regrow hair.
research Trichoscopic evaluation in oral tofacitinib and oral betamethasone in the treatment of moderate to severe alopecia areata
Oral betamethasone works faster than oral tofacitinib for hair regrowth in alopecia areata.
research MP09-17 METHYLATION OF SRD5A2 IN THE BLOOD AS A NOVEL BIOMARKER TO PREDICT SENSITIVITY TO 5-ARI TREATMENT
SRD5A2 methylation in blood can predict how well someone will respond to finasteride treatment.
research 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.